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Abstract (161 words) 
Animal venoms are typically complex mixtures of inorganic salts, small organic molecules 
(<1 kDa), polypeptides (2-9 kDa), and high molecular weight proteins including enzymes 
(>10 kDa). However, the dominant components of most venoms are peptides and proteins. 
Since most venoms are delivered parenterally to their prey (e.g., via barbs, fangs, or 
harpoons), these venom peptides and proteins must be stable enough to reach their sites of 
action before being degraded or excreted. This has resulted in a preference for recruitment 
into the venom of highly stable molecular scaffolds that are resistant to degradation by 
proteases. Consequently, the vast majority of venom peptides and proteins are cross-braced 
by one or more disulfide bridges and have well-defined tertiary structures. The aim of this 
chapter is to introduce readers to the disulfide-rich architectures that have been recruited 
multiple times into different animal venoms or which are common in certain venomous taxa. 
Issues relevant to the therapeutic use of venom peptides will be briefly discussed. 
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2.1 Introduction 
2.1.1 Venom Peptides 
Animal venoms are heterogenous composite secretions designed for predatory and defensive 
purposes. Their function is to disrupt homeostasis in target organisms following traumatic 
injection of the venom via a specialized envenomation apparatus. Venoms usually contain 
inorganic salts, small organic molecules, as well as a broad range of high molecular weight 
proteins including enzymes. However, cysteine-rich bioactive peptides (<50 amino acid 
residues) and polypeptides (50–150 residues) are the most abundant class of molecules found 
in these secretions. 
 
In recent decades, peptide toxins have taken centre stage because of their modest size and 
compact structure which is often stabilized by conserved disulfide-rich scaffolds that provide 
physicochemical resistance against enzymatic degradation and tissue clearance. Moreover, 
their remarkable structural and functional diversity make them an abundant source of 
templates that can be used as pharmacological probes or for the design of therapeutic 
agents.1,2 Indeed, most venom peptides have the ability to selectively modulate heterologous 
receptors or ion channels with high potency or inhibit enzymes that mediate key biochemical 
processes. 
 
Small, disulfide-rich secreted proteins are found across the phylogenetic spectrum. Recently, 
we described the range of disulfide-rich peptide frameworks found in humans.3 Here we 
describe the diversity of disulfide scaffolds present in venom peptides isolated from well 
studied venomous taxa such as snakes, scorpions, spiders, and cone snails, as well as more 
exotic venomous creatures such as the duck-billed platypus.4-7 
 
2.1.2 Disulfide Frameworks: Structural Skeletons Sustaining Bioactivity 
Venom peptides can dramatically vary in size, ranging from the 7–9 residue contryphans 
isolated from marine cone snails8 to the 14–18 kDa phospholipase A2 (PLA2) enzymes found 
in a variety of snake venoms.9 The most conserved structural feature of these peptides is the 
presence of intra-chain disulfide bonds that stabilise their tertiary structure; even the small 
contryphans contain a single disulfide bond. 
 
We will show in this chapter that only a limited number of disulfide frameworks and three-
dimensional (3D) folds are found among more than 2,000 mature venom mini-proteins 
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reported to date. The structural stability imparted by the disulfide bridges, which allows 
venom peptides to reach their site of action when delivered into prey or predators, is not the 
only reason for their remarkable efficiency. The disulfide framework directs the three-
dimensional fold of these peptides to such an extent that it allows extreme hypervariability of 
the non-cysteine residues within the intercystine loops, thereby allowing the most selective 
and potent venom peptides to be selected throughout the course of evolution. The combined 
structural and functional properties of venom peptides directed toward heterologous receptors 
such as G-protein coupled receptors (GPCRs),11,12 voltage- and ligand-gated sodium, 
potassium, calcium, and chloride channels,13-16 transporters,17-19 or specific subtypes of 
enzymes20-22 makes them a source of molecular ligands of unparalleled richness.1,2,23,24 
 
2.2 Diversity of Disulfide Scaffolds and Tertiary Structures 
In this chapter we define a disulfide-rich mini-protein as a peptide or polypeptide up to 150 
residues in length displaying a cysteine-rich framework where all the cysteine residues are 
involved in intra-chain disulfide bonds and where all Cys-Cys connectivities are known. 
Thus, for the purposes of this analysis, we discarded amino acid sequences containing an odd 
number of cysteine residues (where often one cysteine residue is involved in an inter-chain 
disulfide bond) as well as polymeric disulfide-rich mini-proteins. We describe each class of 
disulfide-rich venom peptides, with an emphasis on their secondary structure, 3D fold, and 
function. 
 
2.2.1 Overview of Framework Richness 
To present the mosaic of the diverse frameworks of disulfide-rich venom peptides we 
surveyed the UniProtKB-SwissProt and TrEMBL databases and retained only proteins that 
were isolated at the protein level and located exclusively in extracellular compartments 
(Figure 2.1).25 We then used a high-throughput algorithm developed in-house to select only 
the mature region of proteins and their associated meta-data (i.e. amino acid sequence, 
cysteine connectivity, domain(s), subcellular location, and 3D structure references). We then 
used PLA2 from Pseudonaja textilis, one of the longest venom polypeptides, as a reference 
(with a 5% tolerance threshold) to retain venom peptide sequences that were less than 162 
residues long and contained an even number of cysteine residues ranging from 2 to 16. By 
selecting proteins with at least 9% cysteine content in order to highlight the role of the 
cysteine framework and to avoid molecules with long inter-cysteine sequences, we obtained a 
set of 2,022 secreted mature proteins. A final sorting of these peptides and polypeptides 
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according to their taxonomic affiliation gave rise to 31 different groups. The great majority of 
these 31 venom-peptide classes belong to venomous eumetazoans from diverse taxa such as 
marine invertebrates (cone snails, sea anemones, stingrays, octopus), arthropods (centipedes, 
hymenopterans, spiders, scorpions), reptiles (snakes, lizards), and mammals (platypus). 
 
[Figure 2.1 near here] 
 
Interestingly, despite the broad diversity of disulfide frameworks uncovered, as illustrated in 
Table 2.1, many belong to defined protein families sharing similar folds or structural motifs. 
This observation has led us to describe, in the first part of this chapter, protein groups from 
different taxa characterized by identical domains and clusters of secondary structures. In the 
second part, we focus on venom peptides with unique disulfide frameworks that tend to be 
taxon-specific.  
 
[Table 2.1 near here] 
 
2.2.2 Consensus Architectures of Venom Peptides 
In this section we review some typical disulfide frameworks found in peptides isolated from 
animal venoms. We explain how the disulfide scaffolds are used to stabilize these molecules 
in a compact and well-defined form by describing the shapes and secondary structures 
usually encountered. We also briefly describe how the functionally critical residues (i.e., the 
peptide pharmacophore), where known, are displayed on the 3D framework. 
 
2.2.2.1 Inhibitor Cystine Knot Toxins 
The inhibitor cystine knot (ICK) motif,26 also known as a “knottin” fold, 27 is particularly 
abundant in spider-venom peptides,28,29 although it can also be found in venom peptides from 
predatory marine cone snails and scorpions.16,30 The ICK motif is composed of six cysteine 
residues distributed in a C–C–CC–C–C pattern, in which the thiol groups of CI–CIV, CII–CV, 
and CIII–CVI form three distinct disulfide bonds (Figure 2.2A–C).31 The CI–CIV and CII–CV 
disulfide bonds and the intervening sections of the peptide backbone form a ring that is 
bisected by the third disulfide bridge (Figure 2.2B), resulting in four hypervariable inter-
cystine loops (Figure 2.2A). This "knotted" architecture confers on ICK peptides quite 
remarkable thermodynamic stability and resistance to proteases.29 The four peptides 
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described below illustrate the core ICK architecture and how it can be elaborated with 
additional disulfide bonds. 
 
ω-Conotoxin MVIIA (Figure 2.2D) is a 25-residue peptide from the venom of the cone snail 
Conus magus. A synthetic version of this peptide is marketed under the trade name ziconitide 
as an analgesic drug for the treatment of intractable chronic pain.32 (See Chapter 9 for more 
details.) MVIIA contains an ICK motif supported by a triple-stranded β-sheet involving 
residues Ala6–Cys8 (b strand 1), Cys20–Arg21 (b strand 2), and Lys24–Cys25 (b strand 
1).33,34 MVIIA exerts its anti-nociceptive action by potently and selectively inhibiting the 
voltage-gated calcium (Cav) channel Cav2.2 via an interaction mediated largely by residues 
Arg10 and Arg21 in loops 2 and 4, respectively.35,36 
 
[Figure 2.2 near here] 
 
Huwentoxin IV from the venom of the Chinese tarantula Haplopelma schmidti also contains 
an ICK motif (Figure 2.2E). Its 3D structure is very similar to that of ω-conotoxin MVIIA 
with two antiparallel β-strands connected by a loop that contains the positively charged 
Arg26 residue that is essential for inhibition of the human voltage-gated sodium (NaV) 
channel NaV1.7.37-39 Loss-of-function mutations in the gene encoding this channel lead to a 
congenital insensitivity pain,40 without any other sensory deficits except anosmia,41,42 and 
consequently this channel is considered an excellent analgesic target.43-46 Thus, there is much 
interest in the potential of this class of spider-venom-derived ICK toxins as potential 
analgesics drugs.46,47 
 
Psalmotoxin 1 (π-theraphotoxin-Pc1a or PcTx1; Figure 2.2F) is a 40-residue peptide isolated 
from the venom of the Trinidad chevron tarantula Psalmopoeus cambridgei. It is a potent and 
selective inhibitor (IC50 ~ 0.5 nM) of acid sensing ion channel (ASIC) 1a.48,49 The structure 
of PcTx1 is dominated by a β-hairpin (Leu21 to Lys35) made of two antiparallel β-strands 
(Leu21–Trp24 and Val32–Lys35), plus a single turn of 310 helix in the second loop (His14–
Asp16), and a β-turn in the third loop (Cys18–Leu21).48,49 The overall structure of PcTx1 is 
stabilized by a typical ICK framework. PcTx1 is currently in preclinical studies for treatment 
of chronic pain50 and stroke.51 
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δ-Hexatoxin-Hv1a (δ-HXTX-Hv1a; Figure 2.2G) from the Blue Mountains funnel-web 
spider Hadronyche versuta is a member of the lethal δ-hexatoxin family that is responsible 
for deaths from envenomation by this family of spiders. δ-HXTX-Hv1a slows down 
inactivation of insect and vertebrate NaV channels and causes a hyperpolarizing shift in the 
voltage-dependence of activation13. This induces spontaneous repetitive firing and 
prolongation of action potentials which results in neurotransmitter release from somatic and 
autonomic nerve endings.13 In humans, this leads to a severe envenomation syndrome that 
includes lachrymation, salivation, skeletal muscle fasciculation, sweating, nausea, vomiting, 
diarrhoea, pulmonary oedema, disturbances in respiration, blood pressure and heart rate, 
followed by severe hypotension and respiratory or circulatory failure.52 
 
δ-HXTX-Hv1a is a 42-residue peptide with a cysteine framework comprising eight cysteine 
residues that form a C–C–CCC–C–C–C pattern with a unique triplet of consecutive cysteine 
residues.53 The eight cysteine residues are engaged in four disulfide bonds with CI–CIV, CII–
CVI, CIII–CVII, CV–CVIII connectivity.52 Although, the cysteine pattern is unique, δ-HXTX-
Hv1a is simply a variant ICK toxin in which an additional disulfide bond has been added to 
stabilise an extended C-terminal region. Three of the four disulfide bonds in δ-ACTX-Hv1a 
(Cys1–Cys15, Cys8–Cys20 and Cys14–Cys31) form a classical ICK motif in which the 
Cys14–Cys31 disulfide bond passes through a 14-residue ring formed by the peptide 
backbone and the Cys1–Cys15 and Cys8–Cys20 disulfide bonds.52 The core ICK region 
contains a classical three-stranded b-sheet comprising Asn6–Trp7 (β strand 1), Met18–Val21 
(β strand 2), and Ser30–Ser33 (β strand 3) (Figure 2.2E). The C-terminal region beyond the 
last Cys residue of the ICK core is unusually long and forms several turns of 310 helix 
(residue Ile35–Lys41) (Figure 2.2E). The fourth, atypical disulfide bond between the C-
terminal Cys42 residue and Cys16 in the ICK core region effectively acts as a molecular 
staple that limits the flexibility of the C-terminal helical extension.52 
 
δ-HXTX-Hv1a is an example of the way in which ICK toxins are commonly elaborated via 
the addition of non-core disulfide bonds. There are numerous examples of ICK toxins in 
which an extended β-hairpin loop (loop 4; see Figure 2.2A) is held in place by an additional 
disulfide bond positioned at the tip of the β strands; examples included the spider-venom 
peptides Aps III54, ω-agatoxin IVA55, and d-palutoxin IT2.56 In some cases, more exotic 
disulfide bonds are present, such as the vicinal disulfide bridge found in loop 2 of k-HXTX-
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Hv1c,57 which is essential for its high-affinity block of insect calcium-activated potassium 
(KCa) channels. 58,59 Since the disulfide bonds strongly direct the 3D fold of ICK toxins, they 
are very permissive to sequence variations in the intercystine loops. As a result, ICK toxins 
have evolved to target a wide range of ion channels and receptors, including CaV, Kv, NaV, 
and KCa, channels, ASICs, transient receptor potential (TRP) channels, and P2X3 receptors. 
Moreover, this sequence plasticity has enabled ICK toxins to serve as templates for the 
design of diagnostic agents and drugs in which residues in the intercystine loops have been 
substituted in order to optimize bioavailability or bioactivitiy.60-62 
 
Two-disulfide toxins with a knottin-like fold have also been described in spiders and 
scorpions.63 In this fold, denoted a disulfide-directed β-hairpin (DDH),57 the N-terminal 
CysI–CysIV disulfide bond found in knottins is absent. At this stage, there is conflicting 
evidence about whether the ICK fold is derived from the DDH fold by addition of a disulfide 
bond (making the DDH fold the plesiotypic state) or vice versa.57,63,64 So-called "double-
knot" toxins have also been described in which two ICK domains are joined in a head-to-tail 
fashion; it appears that these toxins evolved either by duplication and fusion of a single  
ancestral ICK gene65 or transcription-mediated fusion of distinct ICK-encoding genes.66 
 
2.2.2.2 BPTI/Kunitz Inhibitor Domain 
The Kunitz/BPTI (Bovine Pancreatic Trypsin Inhibitor) family are a ubiquitous group of 
cysteine-rich proteinase inhibitors.67 Members of this family contain a conserved cysteine 
framework (C–C–C–C–C–C pattern with connectivity CI–CVI, CII–CIV, CIII–CV) and a 
consensus α/β fold, called the Kunitz domain, responsible for their protease inhibitory 
activity, mainly against serine proteases such as trypsin, chymotrypsin, cathepsin, and 
plasmin.68,69 Kunitz domain peptides have been recruited into a number of animal venoms. 
For example, the Kunitz-type proteinase inhibitor SHPI-1 isolated from the sea anemone 
Stoichactis helianthus (Figure 2.3A),70-72, κ-theraphotoxin-Hh1a (also called huwentoxin-11; 
Figure 2.3B) from the venom of the Chinese bird spider,73, and calcicludin from the venom 
of the Eastern green mamba snake (Figure 2.3C)74,75 all contain Kunitz domains. They share 
a similar elongated structural organization with an α-helix in their C-terminal region 
connected to one of the two (SHPI-1, calcicludin) or three (huwentoxin-11) central β-strands, 
as well as to the N-terminal extremity of the toxin through the CI–CVI and CIII–CV disulfide 
bonds. The remaining disulfide bridge CII–CIV stabilizes the flexible portion of the toxin 
located at the opposite side of the linked N- and C-termini. In SHPI-1 and huwentoxin-11 the 
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key pharmacophoric Arg and Lys residues are located in the first and second loop, 
respectively.73,76 However, although these three peptide toxins have a similar 3D structure, 
they have different specificities of action. While SHPI-1 appears to be primarily a protease 
inhibitor (acting on vertebrate trypsin and chymotrypsin),76 huwentoxin-11 also strongly 
inhibits the Kv1.1 channel,73,77 and calcicludin inhibits CaV1 (L-type) calcium channels with 
an IC50 in the nanomolar range.74 This observation highlights the importance of 
hypervariablity in the protein primary structure and the difficulty of predicting the function of 
venom peptides based solely on structural homology. 
 
[Figure 2.3 near here] 
 
2.2.2.3 Kazal-Like Domain 
According to the MEROPS database,78 members of this family of protease inhibitors contain 
one or multiple consensus Kazal domains in reference to the pancreatic secretory trypsin 
inhibitor SPINK1 originally discovered by Kazal et al. in 1948.79 This domain contains a 
conserved cysteine framework (C–C–C–C–C–C pattern) with disulfide connectivity CI–CV, 
CII–CIV, CIII–CVI as compared to the CI–CVI, CII–CIV, CIII–CV connectivity in the Kunitz 
domain protease inhibitors and CI–CIV, CII–CV, and CIII–CVI connectivity in ICK toxins. The 
consensus core of the Kazal domain usually consists of an α-helix and a small β-hairpin 
cross-linked by two disulfide bonds.80 As Kazal domain-containing mini-proteins can be 
found in many divergent species, this characteristic structure is also present in venom 
peptides like rhodniin, an extremely potent inhibitor of thrombin (Figure 2.4). This 103-
residue (11 kDa) polypeptide was isolated from the assassin bug Rhodnius prolixus and it is 
presumed to be expressed in the saliva of this blood-feeding insect in order to prevent blood 
clotting and thus allow prolonged feeding.81 Homologs are present in many other triatomine 
bugs. Rhodniin contains N- and C-terminal Kazal domains separated by an acidic linker. The 
2.6 Å resolution crystal structure of a rhodniin/bovine α-thrombin complex revealed the 
dominant role of the disc-shaped N-terminal rhodniin domain in the interaction with 
thrombin.82 The N-terminal domain residues Pro9, His10, Ala11, Leu12, His13 and Arg14 
interact with the active-site cleft of thrombin, whereas the C-terminal domain interacts with 
the fibrinogen recognition exosite mainly through electrostatic interactions. 
 
[Figure 2.4 near here]  
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2.2.2.4 WAP Domain 
The four-disulfide whey acidic protein (WAP)-type core domain (also called WAP-4-DSC or 
WFDC)83 is particularly conserved in the subclass of small-secreted cysteine-rich mini-
proteins like elafin or the secretory leukocyte protease inhibitor SLPI for instance, that play 
important roles in host defense as antimicrobials and immunomodulators.84,85 Two snake 
venom peptides belonging to the waprin family, nawaprin from the black-necked spitting 
cobra Naja nigricollis (Figure 2.5A) and omwaprin-a from the inland taipan Oxyuranus 
microlepidotus (Figure 2.5B), contain a single WAP domain and have similar functions.86,87 
These two peptides are of similar length (51 and 50 residues, respectively, which is 
characteristic of WAP domains), and they have the same eight-cysteine scaffold (C–C–C–C–
CC–C–C pattern with disulfide connectivity CI–CVI, CII–CVII, CIII–CV, CIV–CVIII), as well as 
identical secondary structures and tertiary folds. Nawaprin and omwaprin-a possess an 
overall flat shape with a spiral backbone organized in one outer and one inner segment 
stabilized by the four disulfide bridges.86 The outer part contains only a small 310 helix 
connected to the inner segment that comprises an antiparallel β-sheet. Interestingly, whereas 
only hypothetical specificities of action have been formulated for nawaprin, it has been 
demonstrated that contrary to elafin and SLPI, omwaprin-a selectively targets its bactericidal 
activity against certain species of Gram-positive bacteria (Bacillus megaterium and 
Staphylococcus warneri) by causing membrane disruption in a dose-dependent manner; in 
contrast, it is non-toxic to mice.87 Moreover, the same study revealed that the structure and 
disulfide scaffold of omwaprin-a are essential for sustaining the function of the toxin, as 
witnessed by the complete loss of activity upon reduction and alkylation of the cysteine 
residues, even with its six N-terminal pharmacophoric residues still present. 
 
[Figure 2.5 near here] 
 
2.2.2.5 SXC Motif 
The six-cysteine SXC or ShKT motif is found in diverse organisms such as mammals,88,89 the 
nematode Caenorhabditis elegans,90 and cnidarians (sea anemones and jellyfish). The Kv 
channel blocker ShK from the Caribbean sea anemone Stichodactyla helianthus (Figure 
2.6A), and aurelin from the moon jellyfish Aurelia aurita (Figure 2.6B) illustrate this 
diversity. Both peptide toxins contain a unique SXC motif comprising six cysteines arranged 
in a C–C–C–C–C–C pattern with disulfide connectivity CI–CVI, CII–CIV, CIII–CV.91-93 The 
disulfide-rich SXC domain is an all-α motif with two short α-helices linked to portions of the 
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peptide backbone via two disulfide bonds.93-95 The third disulfide bond (CI–CVI) links the N- 
and C-terminal regions of the toxin. The 40-residue aurelin peptide has moderate 
antibacterial activity against Gram-positive Listeria monocytogenes and Gram-negative 
Escherichia coli.93 In contrast, ShK (35 residues, 4.05 kDa) potently inhibits human Kv1.3 
(IC50 ≈ 10–100 pM). This channel is a therapeutic target for autoimmune disease because of 
its upregulation in effector memory T cells. ShK-186, a derivative of ShK with improved 
stability and selectivity for Kv1.3, recently passed Phase Ia clinical trials for treatment of 
multiple sclerosis (see Chapter 10 for further details). 
 
[Figure 2.6 near here] 
 
2.2.2.6 PLA2 
PLA2 enzymes are found in almost all living entities from bacteria to mammals. They are 
essential hydrolytic enzymes involved in various physiological processes such as lipid 
metabolism,96 signal transduction,97 and host defense.98 In the world of venomous animals, 
secreted Ca2+-dependent PLA2s are particularly abundant in snake, bee and wasp venoms. 
PLA2s are at the edge between polypeptides and proteins, being larger than most venom 
peptides, and functionally viable as monomers or homo- or heterodimers. We have chosen to 
illustrate a subtype of secretory PLA2s using three different snake venom mini-proteins: the 
acidic PLA2 5 isolated from the venom of the cobra Naja sagittifera (Figure 2.7A), the basic 
PLA2 notexin from the common tiger snake Notechis scutatus scutatus (Figure 2.7B), and 
ammodytoxin A from the Western sand viper Vipera ammodytes ammodytes (Figure 2.7C). 
These toxins are 118–122 residues in length, and they have different cysteine frameworks. 
PLA2 5 from N. sagittifera contains 16 cysteine residues disposed in a C–C–C–C–CC–C–C–
C–C–C–C–C–C–C–C pattern with disulfide connectivity CI–CX, CII–CXVI, CIII–CVI, CIV–CVII, 
CV–CXV, CVIII–CXIV, CIX–CXII, CXI–CXIII.99 Notexin has 14 cysteine residues (C–C–C–CC–C–
C–C–C–C–C–C–C–C) that form seven disulfide bridges (CI–CVIII, CII–CXIV, CIII–CV, CIV–
CXIII, CVI–CXII, CVII–CX, CIX–CXI).100 Ammodytoxin A also has 14 cysteine residues, 
although their disposition (C–C–CC–CC–C–C–C–C–C–C–C–C) and disulfide connectivity 
(CI–CXIII, CII–CIV, CIII–CXII, CV–CXIV, CVI–CXI, CVII–CIX, CVIII–CX) are not the same as 
notexin.101 Despite their different primary structure (~28% identity) and cysteine 
frameworks, these three members of the PLA2 family share identical secondary elements and 
very similar overall 3D architectures. They all display a central core comprised of three long 
α-helices flanked by a small β-hairpin on the side, as well as two short helical turns in the C-
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terminal region, with the numerous disulfide bridges stabilizing the compact 
structure.99,101,102 Apart from exerting classical PLA2 hydrolytic activities on the 2-acyl 
groups in 3-sn-phosphoglycerides, notexin and ammodytoxin A are also able to increase the 
release of acetylcholine (ACh) at neuromusclar junctions via a mechanism that remains to be 
precisely elucidated.102-107 
 
[Figure 2.7 near here] 
 
2.2.3 Taxon-Specific Disulfide Frameworks 
In the second part of this chapter, we focus on unique disulfide frameworks that are only 
found in specific animal taxa, and describe the 3D architecture of these venom peptides. 
 
2.2.3.1 Neurotoxin III Fold in Sea Anemones (Order Actinaria) 
The first taxon-specific disulfide framework we will discuss is found in neurotoxin III (ATX 
III), a 27-residue peptide isolated from the Mediterranean snakelocks sea anemone Anemonia 
sulcata. ATX III contains six cysteine residues that form a CC–C–C–C–C pattern and are 
organized into three disulfide bonds (CI–CV, CII–CIV, CIII–CVI; Figure 2.8).108-110 ATX III is 
devoid of any regular secondary structure; rather, the 3D structure determined using NMR 
spectroscopy111 reveals a compact architecture containing two distorted type I β-turns (Cys6–
Gly9 and Trp8–Cys11), two inverse γ-turns (Pro12–Gly14 and Gln15–Cys17), and two other 
chain reversals that enable ATX III to adopt an overall globular and twisted fold. ATX III 
slows inactivation of NaV channels in crayfish giant axons.112 However there have been no 
investigations into structure-activity relationships of the toxin. 
 
[Figure 2.8] 
 
2.2.3.2 Snakes (Order Squamates) 
2.2.3.2.1 Snake Three-Finger Toxins 
The three-finger toxins (3FTs) are a snake-specific disulfide-rich peptide family 
characterized by a conserved three-dimensional fold and disulfide framework.113 All 3FTs 
contain four conserved disulfide bridges in their core region, but extra disulfide bonds are 
sometimes present.114 The typical fold of 3FTs is comprised of three β-stranded loops, 
symbolized as fingers, which stretch and diverge from a single globular and hydrophobic 
cysteine-rich core region comprising the four conserved disulfide bonds.115,116 Despite their 
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common three-dimensional topology, 3FTs have diverse pharmacology with toxins from this 
family capable of targeting nicotinic acetylcholine receptors (nAChRs), muscarinic 
acetylcholine receptors (mAChRs), acetylcholinesterase, CaV channels, adrenergic receptors, 
and ASICs.113,117,118 3FTs have been used extensively as molecular probes for studying the 
pharmacology and tissue/cellular distribution of nAChRs.119-121  
 
α-Elapitoxin-Nk2a (Figure 2.9A) is a typical 3FT isolated from the venom of the monocled 
cobra Naja kaouthia. This 71-residue peptide contains 10 cysteine residues (C–C–C–C–C–
C–C–CC–C pattern) that form five disulfide bonds with connectivity CI–CIII, CII–CVI, CIV–
CV, CVII–CVIII, CIX–CX).122-124 α-Elapitoxin-Nk2a contains the three loops typically found in 
3FTs plus two distorted right-handed helical turns at the tip of loop II, stabilized by the fifth 
disulfide bond CIV–CV.123 The monomeric form of the toxin binds selectively and with high 
affinity to the α7 nAChR, thereby triggering paralysis in envenomated prey.125-127 Loop II of 
α-elapitoxin-Nk2a, which is stabilized by the extra disulfide bond and contains the helical 
turns, is crucial for high affinity interaction of the toxin with the α7 nAChR.128-130 
 
[Figure 2.9 near here] 
 
2.2.3.2.2 Snake Disintegrins 
The 3FTs display diverse pharmacology on a conserved structural scaffold. In contrast, 
members of the viper-specific disintegrin protein family share a similar function, namely 
inhibition of platelet aggregation and integrin-dependent cell adhesion, but they encompass a 
wider range of folds than the 3FTs.131,132 To illustrate this structural diversity we discuss 
three disintegrins that exhibit different disulfide scaffolds and 3D folds: jarastatin from the 
South American pit viper Bothrops jararaca (Figure 2.9B), triflavin from the venom of 
Protobothrops flavoviridis (Figure 2.9C), a viper endemic to the Ryukyu islands of Japan, 
and obstutatin from the Asian blunt-nosed viper Macrovipera lebetina obtusa (Figure 2.9D). 
Jarastatin and triflavin are medium-sized disintegrins, with 73 and 70 residues respectively, 
and they contain six disulfide bonds.133-135 Obstustatin is smaller (41 residues) and it contains 
only four disulfide bridges.136,137 Jarastatin and triflavin have identical cysteine patterns (C–
C–CC–C–C–CC–C–C–C–C) but different cysteine connectivities (CI–CIII, CII–CIV, CV–CVIII, 
CVI–CXI, CVII–CIX, CX–CXII and CI–CV, CII–CIV, CIII–CIX, CVI–CVIII, CVII–CXI, CX–CXII 
respectively). Obtustatin has only eight cysteine residues (C–CC–C–C–C–C–C pattern) with 
connectivity CI–CIV, CII–CVI, CIII–CVII, CV–CVIII. The 3D structures of these toxins (note that 
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the jarastatin structure is a theoretical model produced in silico) reveal different overall 
shapes and a lack of major secondary structure elements. Triflavin adopts an elongated and 
rigid structure characterized by a series of turns and two short regions composed of 
antiparallel β-strands.138 This anti-aggregant agent inhibits the interaction between fibrinogen 
and platelets by binding to the glycoprotein IIb-IIIa receptor on the platelet surface.133 
Obtustatin has a compact globular shape comprised almost exclusively of turns without any 
regular secondary structure.137 Obtustatin potently and selectively inhibits the α1/β1 integrin 
via a triad of loop residues (Lys21-Thr22-Ser23) that differs from the usual disintegrin Arg-
Gly-Asp pharmacophore motif.139 
 
2.2.3.3 Marine Cone Snails (Genus Conus) 
Several toxins found in the venom of marine cone snails from the genus Conus display 
unique cysteine scaffolds. We exemplify such peptides with descriptions of ι-conotoxin 
RXIA, α-conotoxin PIVA, and ε-conotoxin TxVA. 
 
2.2.3.3.1 ι-Conotoxins 
ι-Conotoxin RXIA was first discovered in the venom of the piscivorous (fish-hunting) rayed 
cone snail Conus radiatus 140 (Figure 2.10A). ι-Conotoxin RXIA contains 46 residues with 
eight cysteines arranged in an atypical framework (C–C–CC–CC–C–C pattern with disulfide 
connectivity CI–CIV, CII–CVI, CIII–CVII, CV–CVIII).141 ι-conotoxin RXIA has numerous post-
translational modifications (PTMs) in addition to the four disulfide bonds, including 
hydroxyproline at positions 2, 11 and 29 and an unusual D-Phe as the third last residue.141,142 
The 3D structure of ι-conotoxin RXIA comprises a series of turns and two antiparallel β-
strands in a compact globular region stabilized by the four disulfide bonds, as well as a long 
flexible C-terminal tail.141 Electrophysiology experiments revealed that ι-conotoxin RXIA is 
an excitatory peptide that acts as an agonist of frog and mouse NaV1.2, NaV1.6 and NaV1.7 
channels (NaV1.6 > NaV1.2 > NaV1.7) by shifting the voltage-dependence of activation to 
more hyperpolarised potentials.141,143 Mutation of the D-Phe residue to L-Phe caused a two-
fold reduction in affinity towards NaV1.6 and a two-fold faster off-rate, as well as a complete 
inactivity on NaV1.2, indicating that this PTM contributes significantly to toxin reversibility 
and selectivity.141,143 
 
[Figure 2.10 near here] 
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2.2.3.3.2 α-Conotoxins 
α-Conotoxin PIVA from the piscivorous purple cone Conus purpurascens is a typical α-
conotoxin that displays a taxon-specific cysteine framework (Figure 2.10B). This short, 25-
residue conopeptide contains six cysteine residues (CC–C–C–C–C) that form three disulfide 
bonds (CI–CV, CII–CIII, CIV–CVI).144 Like ι-conotoxin RXIA, it is also rich in PTMs, with 
hydroxyproline residues at positions 7, 13, and 20 as well as an amidated C-terminus. Han et 
al. described the overall shape of α-conotoxin PIVA as an “iron” in which the external and 
highly charged hydrophilic Ser15–Arg19 segment is the “handle”, while the rest of the toxin 
forms the “bottom plate”.145 α-Conotoxin PIVA does not contain significant secondary 
structure, with the exception of a single turn of 310 helix formed by residues Ser21–Gly24. 
Like most α-conotoxins, α-conotoxin PIVA inhibits postsynaptic nAChRs, particularly the 
α1/β1/γ/δ subtype.146 
 
2.2.3.3.3 ε-Conotoxins 
ε-Conotoxin TxVA from the venom of the molluscivorus cone snail Conus textile (Figure 
2.10C) is a very short 13-residue peptide with a unique cysteine pattern composed of two 
tandem cysteines (CC–CC) with disulfide connectivity CI–CIII, CII–CIV. TxVA is replete with 
PTMs, including γ-carboxyglutamate at positions 1 and 4, bromotryptophan at position 7, a 
glycosylated threonine at position 10, and hydroxyproline at the C-terminus.147-149 It is the 
prototypic member of the T-superfamily of conotoxins that is defined by the presence of two 
tandem cysteines separated by 4–7 residues.150 The side chains of the two γ-
carboxyglutamate residues create an electronegative patch extending outward from a deep 
cleft.148 On the C-terminal face of the peptide, the glycosylated Thr10 and Hyp13 confine a 
cluster of hydrophobic residues around the brominated Trp7 in the constrained intercysteine 
region.148 It has been suggested that TxVA might target presynaptic CaV channels or GPCRs 
based on the fact that it causes a reduction of calcium influx and neurotransmitter release in 
Aplysia cholinergic synapses.148 However, no unequivocal target has been defined for any 
member of the T-superfamily with the exception of t-CnVA, from the piscivorous cone snail 
Conus consors, which was recently shown to be a micromolar antagonist of the somatostatin 
sst3 receptor.150 
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2.2.3.4 CSα/b Toxins in Scorpions (Order Scorpiones) 
Scorpions and centipedes are the oldest terrestrial venomous taxa, with the oldest scorpion 
fossils dating back 430 million years to the Silurian period.2 Although they inhabit a diverse 
range of habitats, scorpions (~1750 extant species) are far less speciose than their closest 
venomous relatives, the spiders (~45,000 extant species).2 Scorpion venoms are dominated 
by so-called cysteine stabilised α/b (CSα/b) toxins that are evolutionarily derived from 
CSα/b defensins, innate-immunity-related antimicrobial peptides that are found in plants, 
fungi, nematodes, and arthropods.151,152 It was recently demonstrated that only a modest 
number of mutations are required to convert a CSα/b defensin into a neurotoxin.153 Most 
CSα/b scorpion toxins target Kv or NaV channels.152 The core cysteine framework of CSα/b 
scorpion toxins is the C–C–C–C–C–C pattern found in CSα/b defensins, but many toxins are 
elaborated with additional disulfide bonds, as outlined in the examples below. 
  
2.2.3.4.1 Butantoxin (α-KTx12.1) 
The potassium channel toxin α-KTx12.1, also called butantoxin or TsTX-IV, was first 
isolated from the venom of the Brazilian yellow scorpion Tityus serrulatus (Figure 2.11A).154 
This 40-residue peptide contains a cysteine framework composed of eight cysteine residues 
(C–C–C–C–C–C–C–C) with disulfide connectivity CI–CII, CIII–CVI, CIV–CVII, CV–
CVIII).155,156 The CIII–CVI, CIV–CVII, and CV–CVIII disulfide bonds constitute the core disulfide 
framework found in CSα/b defensins, with the N-terminal CI–CII disulfide being an 
elaboration of the core fold. Butantoxin is a typical CSα/b toxin in which an α-helix is 
nestled on the face of a b-hairpin, with this core fold stabilized by the CIII-CVI, CIV-CVII and 
CV-CVIII disulfide bonds.155,157,158 The remaining N-terminal CI–CII disulfide bridge is unique 
to this toxin and does not appear to confer additional stability.155 Butantoxin blocks high-
conductance KCa channels and inhibits Shaker Kv channels with low affinity.154 Preliminary 
SAR studies revealed that His28 is important for interaction with its molecular targets.157 
 
[Figure 2.11 near here] 
 
2.2.3.4.2 Maurotoxin (α-KTx6.2) 
α-KTx6.2, also known as maurotoxin (Figure 2.11B), from the venom of the chactoid 
scorpion Scorpio maurus palmatus is a 34-residue peptide comprising an 8-cysteine scaffold 
(C–C–C–C–C–C–C–C) with disulfide connectivity CI–CV, CII–CVI, CIII–CIV, CVII–CVIII.159-163
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The CI–CV, CII–CVI, and CIII–CIV disulfide bonds constitute the core disulfide framework 
found in CSα/b defensins, with the C-terminal CVII–CVIII disulfide being an elaboration of the 
core fold. The core CSα/b fold is comprised of a single α-helix (Ser6–Gln16) abutting a two-
stranded antiparallel β-sheet (β-strands Lys23–Asn26 and Ser28–Cys31).163 Maurotoxin can 
block the Shaker B channel as well as Kv1.1 (IC50 = 45 nM), Kv1.2 (IC50 = 0.8 nM), and 
Kv1.3 (IC50 = 180 nM) channels with high affinity.160,161,164  
 
2.2.3.4.3 Chlorotoxin 
Chlorotoxin is a 36-residue CSα/b toxin isolated from the venom of the Egyptian scorpion 
Leiurus quinquestriatus quinquestriatus. It contains eight cysteine residues distributed in a 
C–C–C–CC–C–C–C pattern with disulfide connectivity CI–CIV, CII–CVI, CIII–CVII, CV–
CVIII.165,166 In this case, the CII–CVI, CIII–CVII, and CV–CVIII disulfide bonds constitute the core 
disulfide framework found in CSα/b defensins, with the N-terminal CI–CIV disulfide being an 
elaboration of the core fold. Relative to the classic CSα/b defensin fold, chlorotoxin contains 
an additional N-terminal b-strand, which leads to the formation of a three-stranded 
antiparallel b-sheet; the extra disulfide bond links this additional b-strand to the α-helix 
(Figure 2.11C).166 Chlorotoxin induces paralysis in crayfish and cockroaches and inhibits 
small conductance chloride channels isolated from rat epithelia and brain.165,167 Chlorotoxin 
selectively binds to gliomas (a type of malignant brain cancer) and inhibits glioma cell 
invasion by virtue of interactions with annexin A2 and matrix metalloproteinase-2 on the cell 
surface.168,169 Moreover, it was recently reported that chlorotoxin is capable of permeating 
the human blood-brain barrier.170 A chlorotoxin conjugate is currently in clinical trials as an 
imaging agent for intraoperative visualization of cancer foci.171-173 
 
2.3 Discussion 
In this chapter we have provided an overview of the broad diversity of structures encountered 
in secreted venom peptides. In the majority of these small proteins, the three-dimensional 
architecture is maintained by precise and often elaborate disulfide-rich scaffolds. As well as 
providing stability and in many cases resistance to proteases, these rigid disulfide 
frameworks allow pharmacophoric amino acid side chains to be displayed in precise spatial 
orientations, thereby optimising the interaction between these venom peptides and their 
molecular targets. Moreover, the disulfide bonds often direct the three-dimensional 
architecture of these peptides to such an extent that the inter-cystine loops are highly 
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permissive to mutations, thereby facilitating the evolution of new toxic functions on the same 
3D scaffold. The consequence of this is that a single scaffold, such as the ICK motif, can 
support a wide range of pharmacological activities that aid the process of envenomation.  
 
In summary, the disulfide-rich scaffolds found in venom peptides provide stability, resistance 
to proteases, and they facilitate the evolution of high affinity binding and diverse 
pharmacology, traits that make these peptides ideal candidates for drug discovery programs. 
We found that 86 disulfide frameworks account for the 2,022 secreted cysteine-rich peptides 
and polypeptides reported to date. Although some of these disulfide scaffolds are found in 
taxonomically diverse venomous animals (e.g. the ICK, Kunitz, Kazal, WAP, SXC and PLA2 
folds), other scaffolds such as snake 3FTs, scorpion CSa/b toxins, and a-conotoxins are 
found only in specific taxa. The diversity of cysteine-rich venom peptides is certain to exceed 
what is currently known, as only a very small percentage of venomous taxa (<1%) has been 
examined to date. Advances in transcriptomic and proteomic analyses of venoms, which are 
discussed in Chapter 3, are rapidly transforming the field and are likely to lead to the 
discovery of many new disulfide-rich scaffolds in hitherto unstudied venomous animals. 
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Figure Legends 
 
Figure 2.1. Pipeline for the selection of secreted cysteine-rich peptides. (A) The 
UniProtKB/SWISS-PROT and TrEMBL databases were searched for entries supported by 
proteomic evidence (based on Edman sequencing, mass spectrometry, X-ray or NMR 
structure, as well as detection by antibodies) and isolated from any extracellular 
compartment. A step-wise algorithm was designed for retaining only mature fragments from 
the parent precursor proteins, extracting their cysteine-framework and their related meta-data 
(sequences, domains, 3D structure references, structural homologies, phylogenetic groups). 
The PLA2 enzyme from Pseudonaja textilis was used as a reference to apply length and 
cysteine-content thresholds in our query (for more flexibility we added a 5% window in the 
selection criteria). Thus, we selected monomeric proteins up to 162 residues in length with an 
even number of 2 to 16 cysteine residues engaged in intra-chain disulfide bonds and with an 
overall cysteine content of at least 9%. (B) Histogram showing the taxonomic distribution of 
protein hits that were generated using this pipeline. 
 
Figure 2.2. Venom peptides containing an inhibitor cystine knot motif. (A) Structure of 
the spider-venom peptide w-hexatoxin-Hv1a (pdb code 1axh)174 with the three disulfide 
bonds that form the ICK motif highlighted in red and green. The disulfide bridges result in 
four intercystine loops, with the final loop emanating from the C-terminal b sheet (b strands 
shown in blue). (B) The CysI-CysIV and CysII–CysV disulfide bonds in w-hexatoxin-Hv1a 
(shown in green) and the intervening sections of the peptide backbone (shown in grey) form a 
closed loop that is bisected by the CysIII–CysVI disulfide bond. (C) Topology of the ICK 
motif, which comprises an antiparallel b sheet stabilised by a cystine knot. b strands are 
shown in blue and the six cysteine residues that form the cystine knot are labeled I–VI. The b 
sheet comprises two mandatory C-terminal b strands (shown in blue) that house CysV and 
CysVI, and a third N-terminal b strand (shown in translucent blue) that encompasses CysII is 
sometimes present. The two “outer” disulfide bonds are shown in green and the “inner” 
disulfide bridge that bisects the cystine-knot loop is shown in red. (D–G) Amino acid 
sequence and ribbon representations of the three dimensional structure of the ICK toxins w-
conotoxin MVIIA (D), huwentoxin IV (E), psalmotoxin 1 (F), and d-hexatoxin-Hv1a (G). In 
these images and all subsequent structures shown in this chapter, α helices, β strands, and 
disulfide bonds are shown in blue, red, and yellow, respectively. Residues that have been 
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experimentally demonstrated to be critical for toxin function are highlighted in green in the 
amino acid sequence and their side chains are displayed in the 3D structures. The N- and C-
termini are labelled, PDB accession numbers are indicated in parentheses, and the source 
organism and molecular target are indicated. Cysteine connectivities are shown above the 
primary structures. (nh2) indicates that the C-terminus is amidated. 
 
Figure 2.3. Venom peptides containing a BPTI/Kunitz inhibitor motifs. Shown on the 
left are the 3D structures of (A) SHPI-1, (B) huwentoxin-11, and (C) calcicludin. The N- and 
C-termini are labelled and PDB accession numbers are indicated in parentheses. The primary 
structure of these peptides along with their disulfide framework, source organism, and 
molecular function are shown in the right panels of the figure. 
 
Figure 2.4. The Kazal domains of rhodniin from the assassin bug Rhodnius prolixus. 3D 
structure of rhodniin. The N- and C-termini are labelled and the PDB accession number is 
indicated in parentheses. The primary structure of the peptide along with the source organism 
and molecular target and shown below the 3D structure.  
 
Figure 2.5. WAP domains of two members of the waprin family. Left panels show the 3D 
structures of (A) nawaprin determined using NMR spectroscopy, and (B) omwaprin-a 
determined using X-ray crystallography. The N- and C-termini are labelled and PDB 
accession numbers are indicated in parentheses. Right panels show the primary structure and 
disulfide framework of these peptides and list the source organism and molecular function. 
 
Figure 2.6. The SXC folds of ShK and aurelin. Left panels show the 3D structures of (A) 
ShK and (B) aurelin. The N- and C-termini are labelled and PDB accession numbers are 
indicated in parentheses. Right panels show the primary structure and disulfide framework of 
these peptides and list the source organism and molecular function. 
 
Figure 2.7. Structure of PLA2 enzymes from snake venoms. The 3D structures of (A) 
acidic PLA2 5, (B) notexin, and (C) ammodytoxin A are shown at the top of the figure. The 
N- and C-termini are labelled and PDB accession numbers are indicated in parentheses. (D) 
Primary structure and disulfide framework of these PLA2 enzymes. The source organism and 
molecular function are indicated. 
 
 33 
Figure 2.8. Structure of the sea anemone peptide neurotoxin III. Left panel shows the 3D 
structure of neurotoxin III determined using NMR spectroscopy. The N- and C-termini are 
labelled and the PDB accession number is indicated in parentheses. Right panel shows the 
primary structure and disulfide framework of neurotoxin III and lists the source organism and 
molecular function. Note the lack of regular secondary structure.  
 
Figure 2.9. 3FTs and disintegrins from snake venom. Left panels show the 3D structures 
of (A) α-elapitoxin-Nk2a (X-ray; PDB 1ctx), (B) jarastatin (model; PDB 2inh), (C) triflavin 
(X-ray; PDB 1j2l), and (D) obtustatin (NMR; PDB 1mpz). The N- and C-termini are labelled 
and PDB accession numbers are indicated in parentheses. Right panels show the primary 
structure and disulfide framework of these peptides and indicate the source organism and 
molecular function. 
 
Figure 2.10. Taxon-specific disulfide frameworks from cone snail venom. Left panels 
show the 3D structures of (A) ι-conotoxin RXIA, (B) α-conotoxin PIVA, and (C) ε-conotoxin 
TxVA. The N- and C-termini are labelled and PDB accession numbers are indicated in 
parentheses. Right panels show the primary structure and disulfide framework of these 
peptides and indicate the source organism and molecular function. PTMs are indicated as 
follows O = hydroxyproline; f = D-Phe; (Gla) = γ-carboxyglutamate; (BTr) = 
bromotryptophan; (gTr) = glycosylated threonine; (nh2) = amidated C-terminus. 
 
Figure 2.11. The scorpion-specific CSa/b framework. Left panels show the 3D structures 
of (A) butantoxin, (B) maurotoxin, and (C) chlorotoxin. The N- and C-termini are labelled 
and PDB accession numbers are indicated in parentheses. Right panels show the primary 
structure and disulfide framework of these peptides and indicate the source organism and 
molecular function. Note that all three peptides exhibit a core CSa/b defensin fold consisting 
of an a-helix on one face of a 2- or 3-stranded antiparallel b-sheet. 
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